Aisling Capital — 2017 Investments
2 investments dated 2017 · listed companies and verified rows first · show all
Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Sean George(Executive Officer, Director)Randal Scott(Executive Officer, Director)Shelly Guyer(Executive Officer)Lee Bendekgey(Executive Officer)Geoffrey Crouse(Director)
Board seatEric Aguiar· per SEC Form D · $6M raise · filed Jun 2017
Co-investorsCivilization Ventures Management, LlcDecheng CapitalFifty YearsManta Ray VenturesOberland CapitalPrefix Capital+1 more
Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.
AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US
Anthony Fernando(Executive Officer)Todd M Pope(Executive Officer, Director)Joseph P Slattery(Executive Officer)Todd M. Pope(Executive Officer, Director)James J. Martin(Executive Officer)Charles J. Filipi(Executive Officer, Director)
Board seatAftab Kherani· per SEC Form D
Co-investorsSV Health InvestorsQuaker BioVenturesSV Life Sciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.